|
|
 |
|
Viewing report
|
|
|
|
Disease Modification in Rheumatoid Arthritis - The Biologics Boom
Datamonitor, Dec 2005, Pages: 145
The global Rheumatoid Arthritis (RA) market has experienced extraordinary growth over the last decade. This market valued at $4.14 billion in 2004, shows no hint of decline. The explosion in new disease modifying drugs since the late 1990s has resulted in a competitive and rapidly evolving market. However, the recent events in the COX-2 market will continue to impact all arthritis drugs.
Scope of this title:
- Detailed analysis of traditional and biologic DMARDs, with sales and volume forecasts to 2014 for the RA indication alone
- Assessment of current and future opportunities and threats in the RA market across the seven major pharmaceutical markets
- Consideration of key events that may affect revenues in each of the seven major pharmaceutical markets are applied and discussed
- Lifecycle management case studies show how previously successful strategies should be applied in todays market
Highlights of this title:
The key indications required by a new disease-modifying treatment include improvement in physical function, reducing signs and symptoms and inhibiting structural progression. Additional indications in the treatment of early RA and juvenile idiopathic arthritis would allow a new product to compete with the now well-established TNF inhibitors.
The launch of new treatments at a premium cost appears to confer a superior treatment, as exemplified by Abbotts launch of Humira. The variation in key product pricing across different countries for a year of treatment shows that careful selection of launch price is needed to make the product competitive and also ensure good returns.
Japan, as the last market forecast to launch most of the biologics, lags behind and is predicted to show slower uptake of these products. However, the recent launch of Enbrel and forecast launch of Humira in this market is expected to push the biologic class above traditional DMARDs by 2010 in this region.
Reasons to order your copy:
- Assess the impact of events such as Medicare changes, patent expiries and sub-indication approvals on the RA sales of key brand name products
- Quantify the future size of the market, in terms of volume and value, for the RA indication in each of the seven major markets
- Gain insight into opinion leaders thoughts on the challenges facing the RA market
Customers who bought this item also bought
Commercial and Pipeline Perspectives: Rheumatoid Arthritis - Novel Biologics Drive Innovation in the Global RA Market
Stakeholder Insight: Rheumatoid Arthritis - DMARDs Gain Ground as Biologics Competition Intensifies
The Rheumatoid Arthritis Market - Competitive Landscape and Clinical Stage Analysis
Disease Modification In Rheumatoid Arthritis - Pipeline Uptake Inhibited By Anti-Tnfs
Stakeholder Insight: Rheumatoid Arthritis - Biologics Battle Up the Treatment Algorithm
Treatment Algorithms: Rheumatoid Arthritis 2nd Edition - Dmards Move to Front of Pack
Rheumatoid Arthritis Drug Discoveries: What The Future Holds
Stakeholder Opinions: Systemic Lupus Erythematosus - Market Set to Enter Era of Biologic Therapies
Pipeline Insight: Disease Modification In Rheumatoid Arthritis - Competition For The Anti-TNF Failure Patient Population Increases
Rheumatoid Arthritis: Market Trends and R&D Insights
Therapeutic Clinical Intelligence - Rheumatoid Arthritis - 2009 Edition
Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
|
|
|
|
